Atea Pharmaceuticals (AVIR) to Release Earnings on Monday

Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) will likely be announcing its Q1 2025 earnings results after the market closes on Monday, May 12th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter.

Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) last announced its quarterly earnings data on Thursday, March 6th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.05). On average, analysts expect Atea Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Atea Pharmaceuticals Stock Down 3.4 %

Shares of NASDAQ:AVIR traded down $0.10 during midday trading on Wednesday, hitting $2.71. The stock had a trading volume of 372,683 shares, compared to its average volume of 301,697. The company has a market cap of $231.49 million, a P/E ratio of -1.31 and a beta of 0.17. Atea Pharmaceuticals has a 12 month low of $2.60 and a 12 month high of $4.15. The business's 50-day simple moving average is $2.94 and its 200-day simple moving average is $3.13.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. William Blair reissued an "outperform" rating on shares of Atea Pharmaceuticals in a research report on Friday, March 7th. Morgan Stanley reduced their price target on Atea Pharmaceuticals from $6.20 to $6.00 and set an "equal weight" rating for the company in a report on Friday, April 11th.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.